KFDA drafted revised new drug registration provision.

Published: 1999-04-29 11:27:00

Updated: 1999-04-29 11:27:00

The KFDA plans to held a public hearing at the auditorium hall of the KPA on April 27 over the revised draft of new drug registration system replacing the current domestic clinical phase III study obligated to a new drug of foreign origin with so called a bridging study. The followings are summar...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK